P14: Compliance and impact of screening of individuals at high risk of hereditary colorectal cancer

Carmen Guillén-Ponce1, María-Teresa Salazar-López2,  Beatriz Peñas3, Tamara Redondo2, Jesús Solera4, Pilar Martínez4, Reyes Ferreiro1, Vanessa Pachón-Olmos1, María-Isabel Humanes2.

1 – Oncology Department, Ramon y Cajal University Hospital, IRYCIS, MADRID, Spain. Red Temática de Investigación Cooperativa en Cancer, Instituto Carlos III, Spanish Ministry of Science and Innovation. 2 – Oncology Department, Ramon y Cajal University Hospital, MADRID, Spain. 3 – Digestive Department, Ramon y Cajal University Hospital, MADRID, Spain. 4 – Molecular Genetic Laboratory, La Paz University Hospital, MADRID, Spain.


The aim of this study was to determine the compliance and impact of screening follow-up in individuals with Lynch Syndrome (LS), in terms of the detection of polyps and cancer.


Between 02/12/2011 and 12/31/2015, 189 individuals underwent regular follow-up. All patients met Bethesda criteria. The genetic study of mismatch repair (MMR) genes was done in 75 individuals (42 had a mutation; 7 had variants of unknown significance; 26 had a non-informative result). At baseline, 115 patients had cancer and 74 were healthy individuals. Compliance and results of the screening tests were evaluated annually.


Of the 189 individuals, 26 (13.7%) did not perform the recommended screening. The reasons were: 9 (4.8% of 189) physician didn’t prescribe the tests; 2 (1%) citation problems; 6 (3.2%) due to the patient; 9 (4.8%) for others. During the follow-up period, 33/189 (17.5%) individuals had polyps. No new colon cancers were diagnosed. Two patients were diagnosed with a lung cancer and a pancreatic neuroendocrine tumour, respectively.


Almost 14% of the patients do not meet the recommended screening for LS. The most important limitation for compliance is the physician. Adenomatous polyps in colon were detected by the screening but no colon cancer or other related cancers.